Association between obsessive-compulsive symptoms, clozapine, and other antipsychotic treatment in psychotic disorders: a systematic review and meta-analysis of epidemiological findings.
Abstract
INTRODUCTION Obsessive-compulsive symptoms (OCS) and obsessive-compulsive disorder (OCD) are common in schizophrenia spectrum disorders (SCZ), yet their aetiology remains unclear. Antipsychotics, particularly clozapine (CLZ), have been implicated, but the strength and consistency of this association remain uncertain.
Methods
A systematic review and random-effects meta-analysis was conducted to evaluate the incidence and prevalence of OCS and OCD in psychosis, comparing people treated with CLZ and other antipsychotics, including first and second generation.
Results
The search identified thirty two studies. The prevalence of OCS was similar between the CLZ-treated and the non-CLZ groups [41%, 95% CI: 28-54% vs. 30%, 95% CI: 22-38%; p=0.183]. In contrast, OCD prevalence was significantly higher in the CLZ group [25%, 95% CI: 18-33% vs. 12%, 95% CI: 7-18%; p=0.007]. De novo outcomes did not differ significantly between groups, de novo OCS was 26% [95% CI: 17-36%] with CLZ versus 14% [95% CI: 7-21%] with non-CLZ antipsychotics (p=0.239), and de novo OCD was 22% [95% CI: 9-36%] versus 19% [95% CI: 17-21%] (p=0.458). In the two studies that had measured the incidence of de novo OCS or OCD, the incidence rate was zero in all groups.
Conclusions
These findings suggest a potential association between CLZ and increased rates of OCS and OCD in cross-sectional studies, though longitudinal evidence is lacking. Methodological limitations, including detection bias, confounding by indication and limited prospective data, highlight the need for further longitudinal and pharmacoepidemiologic research to clarify causal pathways.